Market models for "Teva stock forecast 2025" highlight potential EPS acceleration by 8–12%, tied to robust pipeline developments in neurology and oncology. This aligns with historical sector performance, where regulated drug markets offer defensive growth during economic uncertainty. Sales of Copaxone, a key multiple sclerosis treatment, fell by 23%, contributing just $62 million in revenue for the quarter. On a more positive note, Teva’s innovative portfolio saw impressive growth. Democrats rally around healthcare in shutdown fight, hoping for edge in 2026 Analysts project the "Teva stock forecast 2025" to reflect steady earnings growth, supported by cost optimization and increased generics demand. Consensus estimates place revenue around $16.5B, with EPS moving toward $3.50, indicating mid-teen percentage upside from current prices if multiples sustain near 9–10x forward earnings.